» Articles » PMID: 30760294

Dynamic Inosinome Profiles Reveal Novel Patient Stratification and Gender-specific Differences in Glioblastoma

Overview
Journal Genome Biol
Specialties Biology
Genetics
Date 2019 Feb 15
PMID 30760294
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adenosine-to-inosine (A-to-I) RNA editing is an essential post-transcriptional mechanism mediated by ADAR enzymes that have been recently associated with cancer.

Results: Here, we characterize the inosinome signature in normal brain and de novo glioblastoma (GBM) using new metrics that re-stratify GBM patients according to their editing profiles and indicate this post-transcriptional event as a possible molecular mechanism for sexual dimorphism in GBM. We find that over 85% of de novo GBMs carry a deletion involving the genomic locus of ADAR3, which is specifically expressed in the brain. By analyzing RNA editing and patient outcomes, an intriguing gender-dependent link appears, with high editing of Alus shown to be beneficial only in male patients. We propose an inosinome-based molecular stratification of GBM patients that identifies two different GBM subgroups, INO-1 and INO-2, which can identify novel high-risk gender-specific patient groups for which more aggressive treatments may be necessary.

Conclusions: Our data provide a detailed picture of RNA editing landscape in normal brain and GBM, exploring A-to-I RNA editing regulation, disclosing unexpected editing implications for GBM patient stratification and identification of gender-dependent high-risk patients, and suggesting COG3 I/V as an eligible site for future personalized targeted gene therapy.

Citing Articles

Epitranscriptomics in the Glioma Context: A Brief Overview.

Santamarina-Ojeda P, Fernandez A, Fraga M Cancers (Basel). 2025; 17(4).

PMID: 40002173 PMC: 11853273. DOI: 10.3390/cancers17040578.


REMR: Identification of RNA Editing-mediated MiRNA Regulation in Cancers.

Zhou X, Liu H, Hou F, Zheng Z, Cao X, Wang Q Comput Struct Biotechnol J. 2024; 23:3418-3429.

PMID: 39386942 PMC: 11462282. DOI: 10.1016/j.csbj.2024.09.011.


Bioinformatics for Inosine: Tools and Approaches to Trace This Elusive RNA Modification.

Bortoletto E, Rosani U Genes (Basel). 2024; 15(8).

PMID: 39202357 PMC: 11353476. DOI: 10.3390/genes15080996.


Increased A-to-I RNA editing in atherosclerosis and cardiomyopathies.

Mann T, Kopel E, Eisenberg E, Levanon E PLoS Comput Biol. 2023; 19(4):e1010923.

PMID: 37036839 PMC: 10085048. DOI: 10.1371/journal.pcbi.1010923.


The RNA editing landscape in acute myeloid leukemia reveals associations with disease mutations and clinical outcome.

Meduri E, Breeze C, Marando L, Richardson S, Huntly B iScience. 2022; 25(12):105622.

PMID: 36465109 PMC: 9713371. DOI: 10.1016/j.isci.2022.105622.


References
1.
Chen C, Cho D, Wang Q, Lai F, Carter K, Nishikura K . A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA. 2000; 6(5):755-67. PMC: 1369955. DOI: 10.1017/s1355838200000170. View

2.
Higuchi M, Maas S, Single F, Hartner J, Rozov A, Burnashev N . Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000; 406(6791):78-81. DOI: 10.1038/35017558. View

3.
Wang Q, Khillan J, Gadue P, Nishikura K . Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science. 2000; 290(5497):1765-8. DOI: 10.1126/science.290.5497.1765. View

4.
Maas S, Patt S, Schrey M, Rich A . Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A. 2001; 98(25):14687-92. PMC: 64742. DOI: 10.1073/pnas.251531398. View

5.
Adams J . Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today. 2003; 8(7):307-15. DOI: 10.1016/s1359-6446(03)02647-3. View